UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer

Digestive and liver disease, 2024-06

2024

Volltextzugriff (PDF)

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer

The oncologist (Dayton, Ohio), 2024-05

2024

Volltextzugriff (PDF)

1520P Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial

Annals of oncology, 2023-10, Vol.34, p.S856-S856

2023

Volltextzugriff (PDF)

Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study

International journal of cancer, 2023-10, Vol.153 (7), p.1376-1385

2023

Volltextzugriff (PDF)

Identification of protease-sensitive but not misfolding PNLIP variants in familial and hereditary pancreatitis

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2023-08, Vol.23 (5), p.507-511

2023

Volltextzugriff (PDF)

Chimiothérapie par oxaliplatine normalisée à la quantité de masse maigre pour des cancers du côlon de stade III traités en adjuvant : impact sur les neurotoxicités à partir d’une étude randomisée multicentrique de phase II (LEANOX)

Nutrition clinique et métabolisme, 2023-05, Vol.37 (2), p.e57-e58

2023

Volltextzugriff (PDF)

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort

Cancer medicine (Malden, MA), 2023-03, Vol.12 (5), p.5341-5351

2023

Volltextzugriff (PDF)

LEANOX: Lean body mass normalization of oxaliplatin-based chemotherapy for patients with stage III colon cancer treated in adjuvant setting: Impact on oxaliplatin-induced sensitive neurotoxicity—A multicenter phase II randomized trial

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.92-92

2023

Volltextzugriff (PDF)

1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)

Annals of oncology, 2022-09, Vol.33, p.S1136

2022

Volltextzugriff (PDF)

LBA60 Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study

Annals of oncology, 2022-09, Vol.33, p.S1426

2022

Volltextzugriff (PDF)

WikiMeSH: Multi Lingual MeSH Translations via Wikipedia

Studies in health technology and informatics, 2022-05, Vol.294, p.403

2022

Volltextzugriff (PDF)

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer

Clinics and research in hepatology and gastroenterology, 2022-05, Vol.46 (5), p.101888-101888, Article 101888

2022

Volltextzugriff (PDF)

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

Journal of clinical oncology, 2021-10, Vol.39 (29), p.3242-3250

2021

Volltextzugriff (PDF)

394P Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial

Annals of oncology, 2021-09, Vol.32, p.S535-S535

2021

Volltextzugriff (PDF)

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin

Digestive and liver disease, 2021-07, Vol.53 (7), p.824-829

2021

Volltextzugriff (PDF)

Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study

Journal of geriatric oncology, 2021-05, Vol.12 (4), p.668-671

2021

Volltextzugriff (PDF)

Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study: J Geriatr Oncol

Journal of geriatric oncology, 2020-09

2020

Volltextzugriff (PDF)

Littératie(s) plurilingue(s) dans le contexte de l'apprentissage et de l'enseignement des langues – des perspectives complémentaires

Bulletin VALS-ASLA, 2020-04, p.1

2020

Volltextzugriff (PDF)

Predicting severe toxicity of targeted therapies in elderly patients with cancer (PreToxE): A multicenter, prospective, and retrospective study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.11550-11550

2019

Volltextzugriff (PDF)

781TiPPRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)

Annals of oncology, 2018-10, Vol.29, p.viii266-viii267

2018

Volltextzugriff (PDF)

On the Sociolinguistic Embedding of Portuguese Heritage Language Speakers in Switzerland: Socio-Economic Status and Home Literacy Environment (HELASCOT Project)

Heritage and School Language Literacy Development in Migrant Children, 2018, p.34-57

2018

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study

1520P Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial

Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study

Identification of protease-sensitive but not misfolding PNLIP variants in familial and hereditary pancreatitis

Chimiothérapie par oxaliplatine normalisée à la quantité de masse maigre pour des cancers du côlon de stade III traités en adjuvant : impact sur les neurotoxicités à partir d’une étude randomisée multicentrique de phase II (LEANOX)

Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort

LEANOX: Lean body mass normalization of oxaliplatin-based chemotherapy for patients with stage III colon cancer treated in adjuvant setting: Impact on oxaliplatin-induced sensitive neurotoxicity—A multicenter phase II randomized trial

Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study

1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)

LBA60 Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study

WikiMeSH: Multi Lingual MeSH Translations via Wikipedia

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

394P Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin

Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study

Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study: J Geriatr Oncol

Littératie(s) plurilingue(s) dans le contexte de l'apprentissage et de l'enseignement des langues – des perspectives complémentaires

Predicting severe toxicity of targeted therapies in elderly patients with cancer (PreToxE): A multicenter, prospective, and retrospective study

781TiPPRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)

PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)

On the Sociolinguistic Embedding of Portuguese Heritage Language Speakers in Switzerland: Socio-Economic Status and Home Literacy Environment (HELASCOT Project)

Suchergebnisse filtern